News

ALX-0061 targets the interleukin 6 pathway via its IL-6 receptor (IL-6R) and is being developed to treat rheumatoid arthritis (RA) and SLE. The trial is designed to identify

A4 is a new clinical trial evaluating solanezumab in the preclinical stage of Alzheimer’s disease in older individuals who have evidence of amyloid in their brains on a

Par’s ethacrynate sodium is the generic version of Valeant Pharmaceuticals North America division Aton Pharma’s Sodium Edecrin, which is indicated for the treatment of edema. According to the

Today the PBM, CVS Caremark published their 2016 Standard Formulary List of Excluded Drugs for their commercial clients. Effective from January 1, 2016 Zubsolv has been removed from

This latest update to the IBgard market authorization allows for the following additional claims on the product label: – helps improve/relieve symptoms of IBS within 24 hours,– helps

The proposal made by Shire was to combine the companies in an all-stock transaction pursuant to which Baxalta shareholders would receive, for each Baxalta share, 0.1687 Shire ADRs.

This approval allows for the marketing of Omidria in all EU member states plus Iceland, Lichtenstein, and Norway. Cataract surgery and lens replacement are among the most common

The divestiture includes all of IBAM NA’s cyclotron sites and its research and development facilities. Terms of the transaction were not disclosed. IBA Molecular is jointly owned by

"The advancement of our first product candidate into the clinic ahead of schedule is a significant next step toward our mission to address the urgent need for effective